Advertisement
IMTX vs SRRK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMTX is a Hold and SRRK is a Hold.
IMTX in downward trend: 10-day moving average broke below 50-day moving average on September 10, 2026
The 10-day moving average for IMTX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMTX as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IMTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
IMTX moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IMTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in 224 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.846) is normal, around the industry mean (26.782). P/E Ratio (27.608) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. IMTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SRRK in -3.96% downward trend, falling for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SRRK declined for three days, in 260 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRRK as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
SRRK moved below its 50-day moving average on September 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SRRK crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for SRRK entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in 231 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SRRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.585) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRRK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
IMTX | SRRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 98 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 82 | 64 | |
P/E GROWTH RATING 1..100 | 50 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRRK's Valuation (67) in the Biotechnology industry is in the same range as IMTX (78) in the null industry. This means that SRRK’s stock grew similarly to IMTX’s over the last 12 months.
SRRK's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as IMTX (100) in the null industry. This means that SRRK’s stock grew similarly to IMTX’s over the last 12 months.
IMTX's SMR Rating (98) in the null industry is in the same range as SRRK (99) in the Biotechnology industry. This means that IMTX’s stock grew similarly to SRRK’s over the last 12 months.
SRRK's Price Growth Rating (64) in the Biotechnology industry is in the same range as IMTX (82) in the null industry. This means that SRRK’s stock grew similarly to IMTX’s over the last 12 months.
IMTX's P/E Growth Rating (50) in the null industry is somewhat better than the same rating for SRRK (100) in the Biotechnology industry. This means that IMTX’s stock grew somewhat faster than SRRK’s over the last 12 months.
| IMTX | SRRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 78% | N/A |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Advances ODDS (%) | 15 days ago 77% | 17 days ago 80% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMTX’s FA Score shows that 0 FA rating(s) are green while SRRK’s FA Score has 0 green FA rating(s).
- IMTX’s FA Score: 0 green, 5 red.
- SRRK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMTX’s TA Score shows that 4 TA indicator(s) are bullish while SRRK’s TA Score has 4 bullish TA indicator(s).
- IMTX’s TA Score: 4 bullish, 6 bearish.
- SRRK’s TA Score: 4 bullish, 5 bearish.
Price Growth
IMTX (@Biotechnology) experienced а -8.93% price change this week, while SRRK (@Biotechnology) price change was -4.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.49%. For the same industry, the average monthly price growth was -19.00%, and the average quarterly price growth was -19.88%.
Reported Earning Dates
IMTX is expected to report earnings on Nov 17, 2026.
SRRK is expected to report earnings on Nov 18, 2026.
Industries' Descriptions
@Biotechnology (-8.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
|---|---|---|---|---|
| IMTX | 100% | -5.27% | ||
| SLDB - IMTX | 53% Loosely correlated | -13.26% | ||
| VIR - IMTX | 48% Loosely correlated | -6.11% | ||
| ABEO - IMTX | 48% Loosely correlated | -7.76% | ||
| EDIT - IMTX | 47% Loosely correlated | -11.09% | ||
| CELC - IMTX | 47% Loosely correlated | -4.04% | ||
More | ||||
SRRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRRK has been loosely correlated with RYTM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SRRK jumps, then RYTM could also see price increases.
| Ticker / NAME | Correlation To SRRK | 1D Price Change % | ||
|---|---|---|---|---|
| SRRK | 100% | -3.39% | ||
| RYTM - SRRK | 46% Loosely correlated | -3.57% | ||
| CGON - SRRK | 41% Loosely correlated | -1.16% | ||
| CYTK - SRRK | 39% Loosely correlated | -1.86% | ||
| ARVN - SRRK | 39% Loosely correlated | -8.19% | ||
| IMTX - SRRK | 38% Loosely correlated | -5.27% | ||
More | ||||